ArticlePharmacoEconomics2026
Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.
Article in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aimed to derive a Korean value set for the SF-6Dv2.
methodsFollowing an adapted international protocol, an online discrete choice experiment with duration (DCE
resultsModel 9 (based on the Core Module) was selected as the preferred model for its superior logical consistency, including monotonicity of coefficients and avoidance of counterintuitive results. The pain dimension had the largest utility decrement at its worst level (- 0.496), followed by physical functioning (- 0.480), mental health (- 0.391), social functioning (- 0.329), vitality (- 0.178), and role limitations (- 0.138). The utility for the worst possible health state (556555) was estimated at - 1.012, with 31.7% of all states valued as worse than dead. Significant preference heterogeneity was observed across dimensions, indicating substantial individual-level variation in health state valuations. While including death comparisons (Triplet Module) produced less-negative worst-state utilities, it was not recommended as the primary value set due to its non-efficient experimental design and logical monotonicity issues necessitating greater level collapsing.
conclusionWe derived the first Korean SF-6Dv2 value set. This enables quality-adjusted life-year calculations from both SF-36v2 and SF-6Dv2 data, supporting economic evaluations in Korea.
Indexed as
Identifiers
42274976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.